The first step is to measure cardiovascular risk more accurately, think in cumulative exposure rather than only 10-year horizons, use apoB where possible and especially where standard markers are most likely to underrepresent risk, intervene earlier when trajectory, family history, metabolic phenotype, or imaging suggest that the risk is being understated, and keep treatment burden proportional to the quality of evidence and the person in front of the doctor
dependency on foreign pharmaceutical supply chains particularly for antibiotics, generics, and APIs predominantly manufactured in China and India represents a strategic vulnerability that trade policy must address
Rising awareness among healthcare professionals regarding the long-term benefits of GLP-1 receptor agonists for weight reduction and cardiovascular health is contributing to market growth
The Elle interview sharpened that story further: Williams spoke of 30,000-step days, four-hour summer training sessions and her coach raising concerns about her weight in the HBO documentary series Being Serena
10.1016/j.vph.2017.03.003 37
